| First Author | Zhong J | Year | 2017 |
| Journal | Int Immunopharmacol | Volume | 42 |
| Pages | 176-184 | PubMed ID | 27919004 |
| Mgi Jnum | J:331004 | Mgi Id | MGI:6869402 |
| Doi | 10.1016/j.intimp.2016.11.015 | Citation | Zhong J, et al. (2017) Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-gamma, AMPK/Akt/mTOR signaling and autophagy. Int Immunopharmacol 42:176-184 |
| abstractText | Irbesartan (Irb), a unique subset of angiotensin II receptor blockers (ARBs) with PPAR-gamma activation function, has been reported to play a role in renal dysfunction, glucose metabolism, and abnormal lipid profile in diabetic animal models and humans. However, the underlying mechanisms that improve hyperlipidemia and liver steatosis are unclear. This study investigated the effects of Irb on lipid metabolism and hepatic steatosis using the spontaneous type 2 diabetic db/db mouse model. The results demonstrated body and liver weight, food consumption, lipid content in serum and liver tissue, and liver dysfunction as well as hepatic steatosis were increased in db/db mice compared with db/m mice, whereas the increases were reversed by Irb treatment. Moreover, Irb administration resulted in an increase in LC3BII as well as the LC3BII/I ratio through activating PPAR-gamma and p-AMPK and inhibiting p-Akt and p-mTOR, thereby inducing autophagy in the db/db mouse liver. Therefore, our findings suggest that Irb can ameliorate hyperlipidemia and liver steatosis by upregulating the expression of PPAR-gamma, activating the AMPK/Akt/mTOR signaling pathway and inducing liver autophagy. |
